AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03085433 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microfluidic Sperm Sorting
Description: Microfluidic technology isolates healthy sperm by laminar flow, creating gradients through channels. The microfluidic chip we plan to study in our randomized clinical trial utilizes space-constrained microfluidic sorting to select highly motile and morphologically normal sperm in a flow and chemical-free design. Unlike the standard of density gradient centrifugation, no manipulation of sperm is required in this process. Raw semen is introduced into the inflow and only motile and morphologically normal sperm are able to swim through the chip to the outflow where it is collected for use.
Study NCT03085433 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: in vitro fertilization
Description: ivf/icsi
Study NCT03085433 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: in vitro fertilization
Description: ivf/icsi
Study NCT01475266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EO9 (Apaziquone)
Description: 4 mg/40 mL, Intravesical instillation, Single dose within 6 hours after TURBT
Study NCT01475266 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 40 mL, Intravesical instillation, Single dose within 6 hours after TURBT
Study NCT02299349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine liposome suspension
Description: bupivacaine liposome suspension periarticular injection
Study NCT02299349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: concentrated multi drug Ketorlac, Morphine PF, Epinephrine, Ropivicaine, 0.9% NaCL
Description: Ketorolac 30 mg, Morphine PF 5 mg, Epinephrine 0.6 mg, Ropivacaine 400 mg, QS to 100ml with 0.9% NaCl
Study NCT00457119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: 5mg oral tablets of RAD001 - for the 5mg/daily arm, 10mg oral tablets x 3 of RAD001 - for the 30mg/weekly arm
Study NCT01319838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: >12 kg: 160 mg/m2/day, given PO, divided BID \<=12 kg: 5.33 mg/kg/day, given PO, dividied BID doses given days 1-14 of 28 day cycle for 24 consecutive cycles
Study NCT04418479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Randomization will be performed 1:1 between clopidogrel and aspirin monotherapy in patients who completed standard duration of dual antiplatelet therapy (DAPT) and who were at high risk for recurrent ischemic events after percutaneous coronary intervention (PCI) with drug-eluting stent (DES).~This group will be taken aspirin 100 mg once daily during the study period.
Study NCT04418479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Randomization will be performed 1:1 between clopidogrel and aspirin monotherapy in patients who completed standard duration of dual antiplatelet therapy (DAPT) and who were at high risk for recurrent ischemic events after percutaneous coronary intervention (PCI) with drug-eluting stent (DES).~This group will be taken clopidogrel 75 mg once daily during the study period.
Study NCT03056313 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Proactive support of labor
Description: In case of delayed labor, active labor is defined at an earlier stage; labor support is given with 1 cm opening of the cervix and painful contractions. Labor support interventions are started then.
Study NCT03056313 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: support of labor as usual
Description: In case of delayed labor, active labor start is defined as usual at 3-4 cm opening of the cervix and regular contractions. Labor support interventions are started then.
Study NCT01624493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC4 on day 1 of 21-day cycle, for a maximum of 6 cycles.
Study NCT01624493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine escalations 800 and 1000 mg/m2 (as determined in phase I) on days 1 and 8 of a 21 day cycle, for a maximum of 6 cycles.
Study NCT03039270 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: With sonic activation (SMART Device®)
Description: The operator applied a desensitizing gel containing 5% potassium nitrate and 2% sodium fluoride (Desensibilize KF 2%, FGM, SC, Brazil) on the vestibular surfaces of the participant's anterior teeth. In the sonic activation side, immediately after the gel's application, sonic activation(Smart Sonic Device, FGM, SC, Brazil) was performed for 1.5 minutes in total for side (30 seconds per tooth). After the time of 30 seconds in each of the three anterior teeth of the respective side, the gel was removed from teeth with cotton. After removal of the desensitizing gel, gingival tissues were isolated and the bleaching gel were applied.
Study NCT03039270 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control (Without sonic activation)
Description: The operator applied a desensitizing gel containing 5% potassium nitrate and 2% sodium fluoride (Desensibilize KF 2%, FGM,SC, Brazil) on the vestibular surfaces of the participant's anterior teeth. In the side allocated for application without sonic activation, gel was kept for 10 minutes, after which it was removed from the teeth. After removal of the desensitizing gel, gingival tissues were isolated and the bleaching gel were applied.
Study NCT01624493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 4 on day 1 of a 21 day cycle, for a maximum of 6 cycles.
Study NCT03039426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 0.5% bupivacaine 20ml divided in two; 10 ml intraperitoneal infiltration and 10 ml subcutaneous infiltration
Study NCT03039426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: diclofenac 75 mg intramuscular, 2 hours postoperation
Study NCT03283384 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Letrozole
Description: Letrozole 2.5 mg daily.
Study NCT03283384 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Dose dense AC-T chemotherapy: consisting of 4 cycles of AC (doxorubicin and cyclophosphamide at a dose of 60 and 600 mg/m² as an i.v. bolus, respectively) 2-weekly, plus G-CSF (6 mg once per cycle) 24-48 hr after chemotherapy, followed by cycles of T (4 cycles docetaxel 100 mg/m² 3-weekly or 12 cycles paclitaxel 80 mg/m2 weekly).
Study NCT03283384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib plus letrozole
Description: Ribociclib 600 mg/day (days 1-21, q4 weeks) plus letrozole 2.5 mg daily (days 1-28, q4 weeks).
Study NCT01624493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 800 or 1000 mg/m2 (as determined in phase I) on days 1 and day 8 of 21-day cycle, for a maximum of 6 cycles.
Study NCT02505087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine followed by Placebo
Description: Arm receiving N-Acetylcysteine (NAC) for 6 months and then placebo for 6 months.~Treatment periods are separated by a 2 month washout.
Study NCT02505087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo followed by N-Acetylcysteine
Description: Arm receiving placebo for 6 months then N-acetylcysteine (NAC) for 6 months. Treatment periods are separated by a 2 month washout.
Study NCT04421300 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smile exercise
Description: Launch the smile face recognition APP on smart phone, after user guidance and pretest, a smile exercise will display on the phone, while facing the front camera on the phone, participant will do an exercise emphasizing facial movements, as exaggerated as possible. The exercise last for 8 weeks and 4 times a day
Study NCT04421300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1% sodium hyaluronate eye drop
Description: 0.1% sodium hyaluronate, 4 times a day, the time is in the morning, lunchtime, afternoon and evening. the interval between two training time is 2 hours, 1 hour before and after can be added or subtracted by users, 8 weeks.
Study NCT00948129 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation Intervention
Description: Undergo standard of care smoking cessation intervention
Study NCT00948129 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Intervention
Description: Undergo standard of care smoking cessation intervention
Study NCT01624493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNC105P
Description: BNC105P as determined in phase I, on days 2 and 9 of a 21 day cycle for a maximum of 6 cycles, followed by single agent maintenance BNC105P 16 mg/m2 for a maximum of 6 additional cycles.
Study NCT00948129 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Undergo telephone based smoking cessation intervention
Study NCT00948129 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco Cessation Counseling
Description: Undergo smoking cessation counseling
Study NCT04012502 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Toxicities reduced treatment
Description: Two cycles docetaxel+cisplatin (TP) induction chemotherapy followed by reducing radiation dose(60Gy/30Fx) and omitting concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 50% Partial Response(PR)
Study NCT04012502 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional treatment
Description: Two cycles docetaxel+cisplatin (TP) induction chemotherapy followed by concurrent cisplatin chemoradiotherapy with standard radiation dose (70Gy/35Fx) when responses to induction chemotherapy are less than 50% Partial Response(PR)
Study NCT01289275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patches
Description: Subjects randomized into the patch condition will receive 8 weeks of nicotine patches at discharge. The kit will contain 4 weeks of 21mg patches, 2 weeks of 14mg, and 2 weeks of 7mg.
Study NCT01289275 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Counseling
Description: Up to 5 proactive counseling sessions from California Smokers' Helpline.
Study NCT01289275 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Hospital Counseling
Description: All subjects receive bedside counseling either from Respiratory Therapists or nurses according to the hospital's particular practices.
Study NCT01289275 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Hospital Counseling
Description: All subjects receive bedside counseling either from Respiratory Therapists or nurses according to the hospital's particular practices.
Study NCT01610219 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Modification for Type 2 Diabetes Prevention
Description: Family based behavioral intervention utilizing Traffic Light Diet, self monitoring, goal setting, reinforcement and a tool kit containing physical activity-promoting items
Study NCT01610219 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nutrition and Physical Activity
Description: This family based education program provided information on physical activity and healthy eating for parents and children.
Study NCT00954629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: strontium chloride hexahydrate
Description: Topical solution to be applied twice daily for 26 weeks. Dosage of up till 4 ml per application.
Study NCT00954629 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical solution to be applied twice daily for 26 weeks. Dosage up till 4ml per application.
Study NCT01040091 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emtricitabine (FTC)
Description: 200 mg once a day
Study NCT01040091 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil fumarate (TDF)
Description: 300 mg once a day
Study NCT06793878 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Living in Families With Emotions
Description: This is an 8-week group-based psychosocial intervention teaching adolescents how to recognize their feelings, manage them, and talk about emotions through group discussions, live exercises, and games. The adolescents' caregivers are also provided with the same information, through two live sessions.
Study NCT01040091 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz (EFV)
Description: 600 mg once a day
Study NCT01040091 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Truvada
Description: 200 mg emtricitabine + 300 mg TDF once a day
Study NCT03090516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba dispersible tablets
Description: Arm C：Ginkgo biloba dispersible tablets，0.15g at a time， three times a day.
Study NCT03090516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Arm A：Aricept 5mg/day
Study NCT03090516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba dispersible tablets and Donepezil
Description: Arm B：Ginkgo biloba dispersible tablets，0.15g at a time， three times a day.Aricept 5mg/day.
Study NCT04378998 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: The intervention group received usual care plus acupuncture for three days. The acupuncture spots: Pericardium-6, Stomach-36, Liver-3 and Yin Tang were used. The control group received usual care.
Study NCT03397433 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information Technology physician assist
Description: The intervention hospitals will have a progress note placed in the electronic health record by a reviewing Infectious Disease specialist that comments on the initial antibiotic choice. The comment is based on an electronic prediction tool (Information Technology physician assist) as to what the best therapy is for the individual patient whose health record is reviewed.
Study NCT03350035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Ganaxolone active
Description: IV
Study NCT03350035 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV Placebo, non-active
Description: IV
Study NCT02005159 — intervention group
Intervention type: OTHER
Intervention: Microbiological studies
Study NCT01948765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xenon and propofol
Description: xenon 30% in oxygen as an adjuvant to propofol target controlled infusion (target of 0.5-1.5µg/ml)
Study NCT01948765 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: propofol
Description: propofol target controlled infusion (target 1.5-2.5µg/ml)
Study NCT01545934 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: The intervention is a multicomponent program designed to prevent excessive gestational weight gain in obese women through modifications of diet, exercise, and behavioral strategies during pregnancy.
Study NCT04547335 — intervention group
Intervention type: DRUG
Intervention: Voriconazole
Description: This is an observational study and only the patients already on voriconazole treatment will be included in the study.
Study NCT03654404 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Psychology Intervention
Description: Weekly phone calls with the study interventionist and positive psychology exercises over an 8-week period. The positive psychology program exercises includes three modules: gratitude-based activities, strength-based activities, and meaning-based activities.
Study NCT00649272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin Chloride Extended-Release Tablets, 15 mg
Description: 15mg, single dose fasting
Study NCT03215758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QAW039
Description: QAW039 once daily
Study NCT03215758 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily
Study NCT05659407 — intervention group
Intervention type: DRUG
Intervention: Belimumab in SLE patients / Rituximab in RA patients
Description: Belimumab and Rituximab are the the investigated treatments, respectively in the SLE and RA group. They are administrated according to the approved indications and in compliance with the current recommendations and the good clinical practice, independently to the aim of the present observational study.
Study NCT02684877 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Study NCT04225052 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: YHP1903
Description: YHP1903 Tab. 1mg
Study NCT04225052 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Champix
Description: Comparator Champix Tab. 1mg
Study NCT03199326 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collaborative Care
Description: CPS caseworkers will explain collaborative care to parents, ask parents to allow communication with an infant's primary care provider, and have willing parents sign a release allowing communication with the infant's provider during the investigation. Caseworkers will make at least two attempts to contact identified providers with parental consent. In the first week, caseworkers will contact the provider, identify the infant, and summarize the child maltreatment concerns. The caseworker will ask whether the provider recognizes any additional strengths or vulnerabilities for the infant. Prior to case closure, caseworkers will provide a summary of investigation findings, disposition, and service referrals including placement changes, safety planning, family preservation, and community resources, with a summary letter delivered to the provider after case closure.
Study NCT02912494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JR-131
Study NCT02912494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Study NCT00733837 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nonspecific, Innocuous, Mechanoreceptor Stimulation
Description: A custom device will be used to provide light manual cervical traction
Study NCT02038140 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Zimmer Trabecular Metal Total Ankle System
Description: Primary or revision total ankle replacement
Study NCT04187508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8154 nebulizer suspension, 20 mg/mL
Description: Subjects will receive AZD8154 from Day 1 to Day 10 (10 consecutive days) by using nebulizer and dosimeter system as inhaled dosing and delivered dose will be 3mg.
Study NCT03655691 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle Formulation
Study NCT03655691 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin, Type A
Description: botulinum toxin, Type A, lower Dose 1, administered once, topically, at Baseline
Study NCT03655691 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin, Type A
Description: botulinum toxin, Type A, higher Dose 2, administered once, topically, at Baseline
Study NCT00227695 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: comparing two maintenance schedules of Rituximab
Study NCT00404677 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: deep inhalation
Description: deep inhalation is comprised of an inhalation manoeuver from FRC to TLC
Study NCT00404677 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: deep inhalation
Description: deep inhalation is comprised of an inhalation manoeuver from FRC to TLC
Study NCT04220684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine Hydrochloride
Description: Given IV
Study NCT04220684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study NCT04187508 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive AZD8154 matching placebo (placebo nebulizer suspension, glucose solution for infusion 50 mg/mL) QD from Day 1 to Day 10 (10 consecutive days) by using nebulizer and dosimeter system as inhaled dosing.
Study NCT01186042 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: No intervention
Study NCT00223808 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robot-Low
Description: 1 hour/day of robot-assisted upper limb exercise therapy in addition to usual physical and occupational therapy
Study NCT04220684 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells
Description: Given via infusion
Study NCT00223808 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robot-High
Description: 2 hours/day of robot-assisted therapy in addition to usual physical and occupational therapy
Study NCT00223808 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: 1 hour/day of additional upper limb therapy that includes exposure to, but no manipulation by the robot
Study NCT06798935 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous platelet-rich stroma
Description: Autologous platelet-rich stroma, which is the combined product of stromal vascular fraction and platelet-rich plasma
Study NCT02172573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole
Study NCT02172573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Study NCT02172573 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pramipexole